Year Established :
2019
Total Number of Staff :
100-500
Main Competitive Advantages :
International Approvals/Standards,Experienced R&D Staff,Large Product Line,Contract Manufacturing (CRO,CMO),Quality Service
Other Competitive Advantages :
• Specialized in complex biologics including bispecific, trispecific antibodies, and fusion proteins
• Proven track record with over 30 biologics supported through IND or clinical phases globally
• High-expression CHO platforms (>12 g/L) with fast cell line development (as short as 4.5 months)
• Integrated CMC capabilities from DNA to commercial supply
• Expertise in prefilled syringe formulation and aseptic filling – top 3 in China
• Flexible production scale with single-use bioreactors (50–2000 L) and three aseptic fill-finish lines
• Robust QA/QC system aligned with FDA, EMA, and NMPA expectations
• Strong project management and cross-functional communication for global clients
Business Type :
Service Provider,Manufacturer
R&D Capacity :
Own Brand
Main Sales Markets :
North America,Central/South America,Western Europe,Eastern Europe,Asia,Middle East,Africa
Product Range :
Adalimumab
Sotatercept
Evolocumab
Burosumab
Hyaluronidase
Lanadelumab
Romiplostim (CHO)
Emicizumab
Mepolizumab
Secukinumab
Dupilumab
Ustekinumab
Sarilumab
Tezepelumab
Guselkumab
Benralizumab
Casirivimab
Imdevimab
Palivizumab
Lecanemab
Denosumab
Pertuzumab
Daratumumab
Pembrolizumab
Atezolizumab
Durvalumab
Cetuximab
Panitumumab
Nivolumab
Rituximab
Trastuzumab
Faricimab
Ranibizumab
Bedinvetmab
Lokivetmab
Frunevetmab
Galcanezumab
Recombinant Zoster Vaccine
.............
Audited Supplier
Pharma Sources Insight January 2025
